DE60041119D1 - Verfahren zur präsentation von (poly)peptiden/proteinen auf bakteriophagenpartikeln via disulfidbindungen - Google Patents

Verfahren zur präsentation von (poly)peptiden/proteinen auf bakteriophagenpartikeln via disulfidbindungen

Info

Publication number
DE60041119D1
DE60041119D1 DE60041119T DE60041119T DE60041119D1 DE 60041119 D1 DE60041119 D1 DE 60041119D1 DE 60041119 T DE60041119 T DE 60041119T DE 60041119 T DE60041119 T DE 60041119T DE 60041119 D1 DE60041119 D1 DE 60041119D1
Authority
DE
Germany
Prior art keywords
poly
proteins
peptides
disulpide
bindings
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60041119T
Other languages
English (en)
Inventor
Corinna Loehning
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morphosys AG
Original Assignee
Morphosys AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26070571&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60041119(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Morphosys AG filed Critical Morphosys AG
Application granted granted Critical
Publication of DE60041119D1 publication Critical patent/DE60041119D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
DE60041119T 1999-07-20 2000-07-20 Verfahren zur präsentation von (poly)peptiden/proteinen auf bakteriophagenpartikeln via disulfidbindungen Expired - Lifetime DE60041119D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99114072 1999-07-20
EP00103551 2000-02-18
PCT/EP2000/006968 WO2001005950A2 (en) 1999-07-20 2000-07-20 Methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds

Publications (1)

Publication Number Publication Date
DE60041119D1 true DE60041119D1 (de) 2009-01-29

Family

ID=26070571

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60041119T Expired - Lifetime DE60041119D1 (de) 1999-07-20 2000-07-20 Verfahren zur präsentation von (poly)peptiden/proteinen auf bakteriophagenpartikeln via disulfidbindungen

Country Status (13)

Country Link
US (3) US6753136B2 (de)
EP (2) EP1990409A3 (de)
JP (1) JP4312403B2 (de)
AT (1) ATE417925T1 (de)
AU (1) AU781396B2 (de)
CA (1) CA2347973C (de)
DE (1) DE60041119D1 (de)
DK (1) DK1144607T5 (de)
ES (1) ES2327382T3 (de)
IL (2) IL142025A0 (de)
NO (1) NO331199B1 (de)
PT (1) PT1144607E (de)
WO (1) WO2001005950A2 (de)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472147B1 (en) * 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
WO2001023619A1 (en) 1999-09-29 2001-04-05 Xenoport, Inc. Compounds displayed on replicable genetic packages and methods of using same
US7037706B1 (en) 1999-09-29 2006-05-02 Xenoport, Inc. Compounds displayed on replicable genetic packages and methods of using same
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
ES2393535T3 (es) * 2000-04-17 2012-12-26 Dyax Corp. Nuevos métodos para construir bibliotecas de paquetes genéticos que presentan de forma colectiva los miembros de una familia diversa de péptidos, polipéptidos o proteínas
AU2002249854B2 (en) 2000-12-18 2007-09-20 Dyax Corp. Focused libraries of genetic packages
EP1385984A4 (de) * 2001-03-21 2007-06-13 Xenoport Inc Auf einem icosaedrischen phagen präsentierte verbindung und verfahren zu deren verwendung
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US7202045B2 (en) * 2001-09-19 2007-04-10 Regents Of The University Of Michigan Detection and treatment of cancers of the lung
US7175983B2 (en) * 2001-11-02 2007-02-13 Abmaxis, Inc. Adapter-directed display systems
AU2003253193B2 (en) * 2002-07-30 2009-07-02 Morphosys Ag Novel tricistronic vectors and uses therefor
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
NZ570811A (en) 2002-11-09 2009-11-27 Immunocore Ltd T cell receptor display
AU2004204095B2 (en) 2003-01-07 2009-07-30 Dyax Corporation Kunitz domain library
CA2555185C (en) 2004-02-06 2020-03-24 Morphosys Ag Anti-cd38 human antibodies and uses therefor
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
SG142330A1 (en) 2004-02-06 2008-05-28 Morphosys Ag De Anti-cd38 human antibodies and uses therefor
WO2006125640A2 (en) 2005-05-24 2006-11-30 Morphosys Ag Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38
EP1855723B1 (de) * 2005-03-08 2013-05-22 Ramot at Tel-Aviv University Ltd. Zielgerichtete arzneistofftragende bakteriophagen
WO2006122797A2 (en) 2005-05-18 2006-11-23 Morphosys Ag Anti-gm-csf antibodies and uses therefor
US8114964B2 (en) 2005-05-19 2012-02-14 Centocor, Inc. Anti-MCP-1 antibodies, compositions, methods and uses
CN106434683B (zh) 2005-10-12 2020-03-13 莫佛塞斯公司 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
CN101356271A (zh) 2005-11-09 2009-01-28 拜耳先灵医药股份有限公司 功能阻断性抗-ed-b-纤连蛋白抗体的鉴别与鉴定
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
MX2008008220A (es) * 2005-12-20 2009-03-04 Morphosys Ag Nueva coleccion de regiones hcdr3 y usos de las mismas.
CA2646048A1 (en) 2006-03-30 2007-11-08 Novartis Ag Compositions and methods of use for antibodies of c-met
EP2420832A1 (de) 2006-05-04 2012-02-22 Abmaxis, Inc. Artenübergreifende und Mehrartenanzeigesysteme
ES2372709T3 (es) 2006-07-05 2012-01-25 Catalyst Biosciences, Inc. Procedimientos de cribado de proteasas y proteasas identificadas por los mismos.
CN101558156B (zh) 2006-12-12 2011-11-23 莫佛塞斯公司 内化
ES2403904T3 (es) * 2007-08-21 2013-05-22 Morphosys Ag Métodos para la formación de enlaces disulfuro
NZ583966A (en) 2007-08-30 2012-04-27 Daiichi Sankyo Co Ltd Anti-epha2 antibody
US8877688B2 (en) * 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
DK3124497T3 (da) 2007-09-14 2020-05-11 Adimab Llc Rationelt designede syntetiske antistofbiblioteker og anvendelser deraf
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
NZ585551A (en) 2007-11-26 2012-06-29 Bayer Schering Pharma Ag Anti-mesothelin antibodies and uses therefor
PL2257624T3 (pl) 2008-02-05 2012-09-28 Medical Res Council Sposoby i kompozycje
US9873957B2 (en) 2008-03-13 2018-01-23 Dyax Corp. Libraries of genetic packages comprising novel HC CDR3 designs
US10485879B2 (en) 2008-04-15 2019-11-26 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Plasma cell cytokine vehicle containing fusion proteins for targeted introduction of siRNA into cells and tissues
CA2720363A1 (en) 2008-04-15 2009-10-22 Bira Arya Compositions and methods for delivering inhibitory oligonucleotides
JP5780951B2 (ja) 2008-04-24 2015-09-16 ダイアックス コーポレーション 新規のｈｃｃｄｒ１、ｃｄｒ２、およびｃｄｒ３設計、ならびに新規のｌｃｃｄｒ１、ｃｄｒ２、およびｃｄｒ３設計を含む、遺伝子パッケージのライブラリ
EP2815766B1 (de) 2008-08-05 2017-07-05 Novartis AG Zusammensetzungen und Verfahren für auf das Komplementprotein C5 gerichtete Antikörper
WO2010028347A2 (en) 2008-09-05 2010-03-11 President & Fellows Of Harvard College Continuous directed evolution of proteins and nucleic acids
WO2010079189A1 (en) 2009-01-09 2010-07-15 Morphosys Ag Display vectors and methods and uses thereof
TWI480050B (zh) 2009-02-10 2015-04-11 Daiichi Sankyo Co Ltd 抗－ｍｓｔ１ｒ抗體及其用途
EP3275900A1 (de) 2009-04-27 2018-01-31 Novartis AG Zusammensetzungen und verfahren zur förderung des muskelwachstums
MX2011011338A (es) 2009-04-27 2012-04-19 Novartis Ag Composiciones y metodos de uso para anticuerpos terapeuticos especificos para la subunidad beta1 del receptor de il-12.
UY32560A (es) 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
NZ596058A (en) * 2009-04-30 2013-08-30 Cytos Biotechnology Ag Influenza hemagglutinin compositions and uses thereof
JP5804521B2 (ja) 2009-05-29 2015-11-04 モルフォシス・アー・ゲー コレクション及びその使用方法
WO2011021146A1 (en) 2009-08-20 2011-02-24 Pfizer Inc. Osteopontin antibodies
WO2011032181A2 (en) * 2009-09-14 2011-03-17 Dyax Corp. Libraries of genetic packages comprising novel hc cdr3 designs
US20110189183A1 (en) 2009-09-18 2011-08-04 Robert Anthony Williamson Antibodies against candida, collections thereof and methods of use
JP5955773B2 (ja) 2009-11-17 2016-07-20 ヤンセン バイオテツク，インコーポレーテツド 改善された細菌膜タンパク質分泌
WO2011062859A1 (en) 2009-11-17 2011-05-26 Centocor Ortho Biotech Inc. Display of disulfide linked dimeric proteins on filamentous phage
ES2551871T3 (es) 2010-01-29 2015-11-24 Morphosys Ag Genotecas combinatorias de anticuerpos de roedor
US9290573B2 (en) 2010-05-06 2016-03-22 Novartis Ag Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies
AU2011249783B9 (en) 2010-05-06 2014-11-06 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (LRP6) antibodies
JP6266343B2 (ja) 2010-07-16 2018-01-24 アディマブ， エルエルシー 抗体ライブラリー
DK2606070T3 (en) 2010-08-20 2017-03-27 Novartis Ag Antibodies for the epidermal growth factor receptor 3 (HER3)
RU2551963C2 (ru) 2010-09-09 2015-06-10 Пфайзер Инк. Молекулы, связывающиеся с 4-1вв
JP2013543382A (ja) 2010-10-05 2013-12-05 第一三共株式会社 破骨細胞関連蛋白質Ｓｉｇｌｅｃ−１５を標的とした抗体
MX353795B (es) 2010-11-19 2018-01-30 Morphosys Ag Coleccion y metodos para su uso.
JP6088438B2 (ja) 2010-12-22 2017-03-01 プレジデント アンド フェローズ オブ ハーバード カレッジ 連続的定向進化
WO2013010955A1 (en) 2011-07-15 2013-01-24 Morphosys Ag Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
CN103974976A (zh) 2011-10-19 2014-08-06 莫佛塞斯公司 用于治疗炎性病症的il17c拮抗剂
CN108341873B (zh) 2011-12-05 2022-03-25 诺华股份有限公司 表皮生长因子受体3(her3)的抗体
EA201491107A1 (ru) 2011-12-05 2014-11-28 Новартис Аг Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен ii her3
US9958437B2 (en) 2012-02-03 2018-05-01 The Governors Of The University Of Alberta Method of quantifying peptide-derivative libraries using phage display
EP2855521A4 (de) 2012-05-24 2016-03-02 Mountgate Group Ltd Zusammensetzungen und verfahren in zusammenhang mit der vorbeugung und behandlung von tollwutinfektion
DK2885639T3 (da) 2012-08-17 2019-07-08 Morphosys Ag Kompleksspecifikke antistoffer og antistoffragmenter og deres anvendelse
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
JP2015536339A (ja) 2012-11-09 2015-12-21 ファイザー・インク 血小板由来増殖因子ｂ特異的抗体ならびにこれらの組成物および使用
US9428577B2 (en) 2012-11-09 2016-08-30 Pfizer Inc. Platelet-derived growth factor B specific antibodies and compositions and uses thereof
WO2014096333A1 (en) 2012-12-20 2014-06-26 Morphosys Ag Anti-staphylococcal antibodies
WO2014159239A2 (en) 2013-03-14 2014-10-02 Novartis Ag Antibodies against notch 3
NZ710929A (en) 2013-03-15 2018-02-23 Novartis Ag Antibody drug conjugates
WO2014167088A1 (en) 2013-04-12 2014-10-16 Morphosys Ag Antibodies targeting m-csf
WO2014170317A1 (en) 2013-04-17 2014-10-23 Morphosys Ag Antibodies targeting specifically human cxcr2
WO2015134121A2 (en) 2014-01-20 2015-09-11 President And Fellows Of Harvard College Negative selection and stringency modulation in continuous evolution systems
JP2017511151A (ja) 2014-03-14 2017-04-20 イムノコア リミテッド Ｔｃｒライブラリ
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
US10920208B2 (en) 2014-10-22 2021-02-16 President And Fellows Of Harvard College Evolution of proteases
TN2017000173A1 (en) 2014-11-14 2018-10-19 Novartis Ag Antibody drug conjugates
ES2904573T3 (es) 2015-03-27 2022-04-05 Univ Southern California Terapia con células T dirigida a LHR para el tratamiento de tumores sólidos
WO2016168631A1 (en) 2015-04-17 2016-10-20 President And Fellows Of Harvard College Vector-based mutagenesis system
WO2016176652A2 (en) 2015-04-29 2016-11-03 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
JP6985934B2 (ja) * 2015-04-29 2021-12-22 フレッド ハッチンソン キャンサー リサーチ センター 操作された造血幹細胞／前駆細胞及び非ｔエフェクター細胞、ならびにその使用
EP3095465A1 (de) 2015-05-19 2016-11-23 U3 Pharma GmbH Kombination von fgfr4-inhibitor und gallensäurekomplexbildner
US10711064B2 (en) 2015-06-04 2020-07-14 University Of Southern California Lym-1 and Lym-2 targeted CAR cell immunotherapy
EA201792561A1 (ru) 2015-06-05 2018-04-30 Новартис Аг Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
WO2017015545A1 (en) 2015-07-22 2017-01-26 President And Fellows Of Harvard College Evolution of site-specific recombinases
US11524983B2 (en) 2015-07-23 2022-12-13 President And Fellows Of Harvard College Evolution of Bt toxins
US10612011B2 (en) 2015-07-30 2020-04-07 President And Fellows Of Harvard College Evolution of TALENs
EA038332B1 (ru) 2015-09-09 2021-08-10 Новартис Аг Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
SI3347377T1 (sl) 2015-09-09 2021-06-30 Novartis Ag Protitelesa, ki vežejo timusni stromalni limfopoietin (tslp) in postopki uporabe protiteles
GB201516272D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516269D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516277D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR libraries
GB201516270D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516274D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516265D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516275D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
AU2016326721C1 (en) 2015-09-23 2021-06-03 Cytoimmune Therapeutics, Inc. FLT3 directed car cells for immunotherapy
US11180546B2 (en) 2016-02-17 2021-11-23 Novartis Ag TGFbeta 2 antibodies
AU2017219837B2 (en) 2016-02-19 2023-08-17 Galapagos Nv Antibodies for IL-17C
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
EP3538552B1 (de) 2016-11-14 2023-09-13 MorphoSys AG Fab-moleküle mit einer nager-hinge-region und einer nichtnager-ch1-region
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2019010164A1 (en) 2017-07-06 2019-01-10 President And Fellows Of Harvard College EVOLUTION OF ARNT SYNTHÉTASES
EP3444275A1 (de) 2017-08-16 2019-02-20 Exiris S.r.l. Monoklonaler antikörper anti-fgfr4
WO2019056002A1 (en) 2017-09-18 2019-03-21 President And Fellows Of Harvard College CONTINUOUS EVOLUTION FOR STABILIZED PROTEINS
WO2019094595A2 (en) 2017-11-09 2019-05-16 Pinteon Therapeutics Inc. Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
AU2018372135A1 (en) 2017-11-22 2020-05-28 Novartis Ag Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
EP3774926A1 (de) 2018-04-05 2021-02-17 Bio-Rad ABD Serotec GmbH Anzeigesysteme für proteine von interesse
EP3793596A1 (de) 2018-05-16 2021-03-24 MorphoSys AG Antikörper gegen glycoprotein vi
WO2019241649A1 (en) 2018-06-14 2019-12-19 President And Fellows Of Harvard College Evolution of cytidine deaminases
US20210277118A1 (en) 2018-06-21 2021-09-09 Daiichi Sankyo Company, Limited Compositions including cd3 antigen binding fragments and uses thereof
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
WO2020182974A1 (en) 2019-03-14 2020-09-17 Morphosys Ag Antibodies targeting c5ar
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
MX2023000547A (es) 2020-07-16 2023-02-13 Novartis Ag Anticuerpos anti-betacelulina, fragmentos de los mismos, y moleculas de union multiespecificas.
EP4217391A1 (de) 2020-09-24 2023-08-02 MorphoSys AG Neue humane antikörper, die an humanes cd3-epsilon binden
US20240115720A1 (en) 2021-01-13 2024-04-11 Memorial Sloan Kettering Cancer Center Antibody-pyrrolobenzodiazepine derivative conjugate
JP2024503658A (ja) 2021-01-13 2024-01-26 メモリアル スローン－ケタリング キャンサー センター 抗ｄｌｌ３抗体－薬物コンジュゲート
TW202323289A (zh) 2021-08-31 2023-06-16 日商大正製藥股份有限公司 抗生長激素抗體
WO2023180346A1 (en) 2022-03-22 2023-09-28 Morphosys Ag Deimmunized antibodies specific for cd3
GB202204159D0 (en) 2022-03-24 2022-05-11 Heptares Therapeutics Ltd Antibodies

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8203855D0 (sv) 1982-06-21 1982-06-21 Astra Laekemedel Ab Novel derivatives of guanine i
DE3852304T3 (de) 1987-03-02 1999-07-01 Enzon Lab Inc Organismus als Träger für "Single Chain Antibody Domain (SCAD)".
AU4308689A (en) 1988-09-02 1990-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5747334A (en) * 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770434A (en) * 1990-09-28 1998-06-23 Ixsys Incorporated Soluble peptides having constrained, secondary conformation in solution and method of making same
US5871974A (en) * 1990-09-28 1999-02-16 Ixsys Inc. Surface expression libraries of heteromeric receptors
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
GB9114003D0 (en) * 1991-06-28 1991-08-14 Mastico Robert A Chimaeric protein
GB9213601D0 (en) * 1992-06-26 1992-08-12 Mastico Robert A Protein based delivery system
CA2115811A1 (en) * 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
GB9313509D0 (en) * 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
US6309642B1 (en) * 1997-04-28 2001-10-30 The Research And Development Institute, Inc. Peptides which mimic candida carbohydrate epitopes and their use in a vaccine
US6341256B1 (en) * 1995-03-31 2002-01-22 Curagen Corporation Consensus configurational bias Monte Carlo method and system for pharmacophore structure determination
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
GB9608540D0 (en) * 1996-04-25 1996-07-03 Medical Res Council Isolation of enzymes
CA2297070A1 (en) * 1997-08-01 1999-02-11 Morphosys Ag Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex
EP1078051B1 (de) * 1998-05-13 2007-12-12 Domantis Limited Phagen-display-selektionssystem für korrekt gefaltete proteine

Also Published As

Publication number Publication date
ES2327382T3 (es) 2009-10-29
NO20011386L (no) 2001-05-18
JP4312403B2 (ja) 2009-08-12
US6753136B2 (en) 2004-06-22
US20020034733A1 (en) 2002-03-21
WO2001005950A3 (en) 2001-08-02
DK1144607T5 (da) 2009-10-05
US20050058984A1 (en) 2005-03-17
NO20011386D0 (no) 2001-03-19
DK1144607T3 (da) 2009-08-24
ATE417925T1 (de) 2009-01-15
AU5986400A (en) 2001-02-05
IL142025A (en) 2009-12-24
US20070292947A1 (en) 2007-12-20
AU781396B2 (en) 2005-05-19
CA2347973C (en) 2010-06-22
PT1144607E (pt) 2009-04-22
JP2003505025A (ja) 2003-02-12
EP1990409A2 (de) 2008-11-12
US7785859B2 (en) 2010-08-31
WO2001005950A2 (en) 2001-01-25
IL142025A0 (en) 2002-03-10
EP1144607A2 (de) 2001-10-17
EP1990409A3 (de) 2011-05-18
EP1144607B1 (de) 2008-12-17
NO331199B1 (no) 2011-10-31
CA2347973A1 (en) 2001-01-25

Similar Documents

Publication Publication Date Title
ATE417925T1 (de) Verfahren zur präsentation von (poly)peptiden/proteinen auf bakteriophagenpartikeln via disulfidbindungen
DE60040333D1 (de) Verfahren zur acylierung von peptiden und proteinen
DE69713112T2 (de) Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin-analogen
PT929574E (pt) Moduladores da agregacao de peptidos beta-amiloides compreendendo d-aminoacidos
DE60031030D1 (de) Verfahren zur Identifizierung von Peptiden und Proteinen mittels Massenspektromterie
PT662827E (pt) Metodos de diagnostico e composicoes farmaceuticas a base de proteinas notch e acidos nucleicos
MX9305729A (es) Formulas de proteinas de liberacion sostenida.
DE60026452D1 (de) Verfahren zur Identifizierung von Peptidensequenzen und Proteinensequenzen mittels Massenspektromterie
DE69823046D1 (de) Praktische in vitro sialylierung von rekombinanten glykpproteinen
WO2002002627A3 (en) Interferon-like protein zcyto21
IL172729A0 (en) Reagents and methods for the formation of disulfide bonds and the glycosylation of proteins
DE3856059D1 (de) Peptid-Determinante mit Einfluss auf die Immunität
DE50012831D1 (de) Verfahren zur verbindung von molekularen substanzen
DE60023860D1 (de) Verfahren zur herstellung von rekombinanten peptiden
ATE236984T1 (de) Verfahren zur herstellung von hydrophoben polypeptiden, proteinen und peptiden
DE59804785D1 (de) Verbessertes Verfahren zur Stabilisierung von Proteinen
ATE223481T1 (de) Peptid der löslichen form von acetylcholinesterase mit aktivität als calciumkanalmodulator
DE60141657D1 (de) Verfahren zur Reinigung von stark anionischen Proteinen
ATE397081T1 (de) Erhöhte expression von proteinen mittels gfp
DE59004279D1 (de) Verfahren zur C-terminalen Modifizierung von Proteinen.
ATE417105T1 (de) Spleissvariante des kopftrauma induzierten zytoplasmatischen calcium-bindenden proteins

Legal Events

Date Code Title Description
8364 No opposition during term of opposition